SCHEMBL4764295

SCHEMBL4764295

N#Cc1cccc(NC(=O)Nc2ncc(-c3cc(C(=O)O)c4cn[nH]c4n3)s2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.44
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PDE10A Q9Y233 2/20 0.41
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PPIA P62937 1/20 0.40
NSD2 O96028 1/20 0.39
KIT P10721 1/20 0.39
PDGFRA P16234 1/20 0.39
CNR1 P21554 1/20 0.39
GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724126 0.88 CNR1 (0.47) MEN1MAPTKMT2AALDH1A1HTT
SCHEMBL4721455 0.87 MEN1 (0.48) MEN1MAPTKMT2AALDH1A1HTT
SCHEMBL4721735 0.84 FLT3 (0.51) MEN1MAPTKMT2ANPC1RAB9A
SCHEMBL4721629 0.84 FLT3 (0.49) MEN1MAPTKMT2AHTTRAB9A
SCHEMBL4765909 0.82 TRPV1 (0.45) CNR1ROCK2ROCK1
SCHEMBL4724468 0.82 MAPT (0.46) BLMMEN1MAPTKMT2AALDH1A1
SCHEMBL4723103 0.82 CNR1 (0.55) MEN1MAPTKMT2AALDH1A1HTT
SCHEMBL1322532 0.82 SMYD2 (0.50) ALDH1A1NPC1HSD17B10
SCHEMBL16456596 0.82 BLM (0.44) BLMMEN1MAPTKMT2AALDH1A1
SCHEMBL4725018 0.80 KDR (0.44) MEN1MAPTKMT2AHTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1912988-B1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA SA (FR) 2014-04-16 EP claimed
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-31 US claimed
EP-1912988-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF Aventis Pharma S.A. (FR) 2008-04-23 EP claimed
WO-2007017577-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2007-02-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof PRMT7, PRKACA, PRKX BLM 3564/4885MEN1 2501/4885MAPT 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.